trial · primary record
Rozanolixizumab
Ocular Myasthenia Gravis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2029-01-22 |
| Primary endpoint | Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome (PRO) part) |
| Registry ID | NCT07463521 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:30:37.849Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07463521
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.